ALVO · Alvotech

Alvotech's capital raise of approximately $152 million in gross proceeds (before expenses) from a public offering and concurrent private placement provides a significant infusion of cash for the company's biosimilar development pipeline. The public offering of 22.7 million shares at $3.75 per share, with the underwriters' option exercised in full for an additional 3.4 million shares, will generate net proceeds of about $91.2 million. The private placement of 17.8 million shares at the same price adds gross proceeds of roughly $66.85 million, though subject to expenses and contingent on the public offering closing. The combined funds are earmarked for continued development of biosimilar assets, including candidates that recently received Complete Response Letters from the FDA, as well as working capital and general corporate purposes. The offering is expected to close on June 17, 2026, with the private placement following within seven business days. This financing strengthens Alvotech's balance sheet as it navigates regulatory hurdles and prepares for potential commercial launches.